Article

Cyclosporine beneficial for treating patients with dry eye

Cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) is beneficial for treating patients with dry eye because it increases goblet cell density and production of transforming growth factor ?2, an immunoregulatory factor, compared with artificial tear formulations, which do not.

Key Points

Houston-Cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) is beneficial for treating patients with dry eye because it increases goblet cell density and transforming growth factor (TGF)-ß2 production compared with artificial tear formulations, which do not.

Reduced conjunctival goblet cell density is a substantial component of chronic dry eye, and a treatment that reverses that process is an obvious boon for patients. In addition, TGF-ß2, an important immunoregulatory factor, is secreted by goblet cells.

Tear formulations have been the mainstay of treatment for patients with dry eye but do not have an effect on goblet cell density, in contrast to treatment with cyclosporine 0.05%, which was found to be associated with increased goblet cell density. Increased goblet cell density has also been associated with decreases in punctate corneal fluorescein staining, blurred vision, and use of artificial tears in patients concomitantly treated with cyclosporine 0.05%.

Six patients (five women, one man; mean age, 56.6 years) with diagnosed dry eye disease participated in their study. Before the study, patients had used various tear formulations (Refresh Plus, Allergan, n = 2; Systane, Alcon Laboratories, n = 2; TheraTears, Advanced Vision Research, n = 1; Genteal, Novartis, n = 1. Upon entrance into the study, the patients instilled one artificial tears formulation (Refresh Plus), four times daily for 4 weeks and then cyclosporine 0.05% twice daily for 12 weeks. Impression cytology was performed bilaterally on the bulbar conjunctiva at baseline, after treatment with artificial tears, and following 6-and 12-week treatment with cyclosporine, and the goblet cells were counted. The membranes from the fellow eye were stained for TGF-ß2.

"After 4 weeks of use of the study artificial tears, no differences in mean goblet cell density were found in temporal and inferior bulbar specimens compared with baseline. However, after 6 weeks of treatment with topical cyclosporine 0.05% ophthalmic emulsion twice a day, the goblet cell density increased by 4.1-fold and 3.1-fold in the temporal and inferior bulbar conjunctiva, respectively, relative to the levels found after treatment with artificial tears only," the investigators reported.

The difference in goblet cell density from baseline in the inferior bulbar conjunctiva reached statistical significance (p < 0.01).

Twelve weeks after the beginning of treatment with cyclosporine, the goblet cell density in the temporal and inferior bulbar conjunctiva increased by 2.8-fold and 3.1-fold, respectively, compared with artificial tear treatment (p < 0.01).

The number of goblet cells that were positive for TGF-ß2 increased after 6 and 12 weeks of therapy with cyclosporine, the investigators reported.

They said, "The findings indicate that cyclosporine inhibits the pathologic mechanisms leading to reduced conjunctival goblet cell density in chronic dry eye disease. In addition to the observed increase in goblet cell density, there was a change in appearance of the conjunctival epithelial cells from loosely adherent larger cells to more tightly adherent sheets of small cells.''

Dr. Pflugfelder and colleagues also cited another important finding, i.e., "the goblet cells function like the lacrimal glands in secreting growth factors into the tear.''

They explained that in a murine model, goblet cells in the conjunctiva produce and secrete TGF-ß2, the same as in humans in this study, and that TGF-ß2 increased after treatment with cyclosporine.

"The implications of normalizing TGF-ß2 concentrations in the tears as a result of cyclosporine therapy have not been determined; however, TGF-ß has been found to have many immunoregulatory effects, including inhibition of lymphocyte proliferation," the authors said.

"It is increasingly clear that normalization of the ocular surface in dry eye requires regeneration of conjunctival goblet cells. Cyclosporine emulsion is the only therapeutic agent thus far that has been demonstrated to have this effect," Dr. Pflugfelder concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.